PLRX
Pliant Therapeutics, Inc.Healthcare·Biotechnology
$1.26
$78M market cap
Revenue
$0.0M
Free Cash Flow
$-37.0M
Rev Growth
+0.0%
FCF Margin
0.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avÃ6 and avÃ1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avÃ1, which completed Phase 1 clinical trial for the treatment of liv
2-Year Price History
$1.21-89.1%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 0.0 | -21.5 | -21.8 | -20.0 | -19.2 | -19.2 | -0.0 | 170.9 | 28.8 | 61.8 | -123.1% | -- | -- |
| Act | 2025-Q4 | 0.0 | -23.1 | -23.6 | -23.6 | -17.8 | -17.8 | -0.0 | 190.9 | 29.1 | 61.4 | -107.2% | -169.7x | -- |
Valuation & Metrics
Market Stats
Price$1.26
Market Cap$78M
Enterprise Value$-64M
P/S Ratio0.0x
P/FCF--
EV/FCF--
FCF Margin (TTM)0.0%
FCF Yield-47.4%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.0M
Net Income$-43.6M
Free Cash Flow$-37.0M
Revenue Growth (YoY)+0.0%
EBITDA Margin0.0%
Net Margin0.0%
FCF Margin0.0%
CapEx % of Revenue0.0%
SBC % of Revenue0.0%
ROIC-115.2%
WC Change % Rev0.0%
Interest Coverage-327.8x
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares3.4M
Days to Cover5.3
Change (vs Prior)-5.8%
Need at least 2 settlement dates for chart
Employees
Headcount171
Revenue / Employee$0
Gross Profit / Employee$-1,544
Cash Runway
55.4months
WATCH
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
73.0%(-7.5% YoY)
76 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
8.1%(-13.6% YoY)
10 filers
Vanguard, iShares, SPDR
Market makers
0.7%(+0.2% YoY)
4 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | $7.7M | $1.35 | +$0 | +$180K | -5.4% | $1.93B |
| CITADEL ADVISORS LLC | $4.1M | $7.01 | +$811K | +$4.1M | -0.4% | $138.22B |
| Blue Owl Capital Holdings LP | $3.7M | $17.06 | +$0 | +$0 | -1.1% | $372M |
| ADAR1 Capital Management, LLC | $3.3M | $2.15 | +$3.2M | +$3.3M | +8.4% | $1.64B |
| ACADIAN ASSET MANAGEMENT LLC | $3.0M | $1.37 | +$65K | +$1.5M | -0.5% | $70.48B |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $3.0M | $1.26 | +$3.0M | +$3.0M | — | $4.04T |
| TWO SIGMA INVESTMENTS, LP | $2.8M | $5.34 | +$1.6M | +$2.5M | -0.9% | $117.03B |
| Monaco Asset Management SAM | $2.4M | $1.21 | +$0 | +$2.4M | +1.9% | $315M |
| RENAISSANCE TECHNOLOGIES LLC | $2.3M | $3.54 | +$1.0M | +$2.1M | +1.2% | $63.91B |
| Prosight Management, LP | $2.1M | $1.23 | +$141K | +$1.7M | -16.0% | $610M |
| Woodline Partners LP | $2.1M | $2.33 | −$453K | −$1.1M | -0.1% | $26.43B |
| BML Capital Management, LLC | $1.9M | $1.22 | +$0 | +$1.9M | -1.6% | $155M |
| Peapod Lane Capital LLC | $1.6M | $1.31 | +$507K | +$797K | +0.0% | $122M |
| MILLENNIUM MANAGEMENT LLC | $1.5M | $5.17 | +$972K | +$1.5M | -0.5% | $127.40B |
| BlackRock, Inc.Passive | $1.4M | $11.05 | +$29K | −$5.2M | -0.2% | $5.69T |
| UBS Group AG | $1.3M | $5.38 | −$6K | −$2.0M | -0.3% | $562.11B |
| MARSHALL WACE, LLP | $1.3M | $2.97 | −$106K | +$992K | +0.6% | $92.71B |
| Eversept Partners, LP | $1.1M | $6.91 | +$62K | +$1.1M | -0.3% | $1.52B |
| JPMORGAN CHASE & CO | $1.0M | $2.91 | −$442K | +$447K | -0.2% | $1.47T |
| Redmile Group, LLC | $973K | $18.85 | −$1.1M | −$1.6M | -5.7% | $1.51B |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BULLISH
Holders
-1.38%
avg per quarter
Holders (ex-self)
-1.25%
excl. this stock
Buyers (this Q)
+1.69%
36 buyers · $0.01B in
Sellers (this Q)
-0.85%
28 sellers · $0.01B out
alpha coverage: 94% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
-14.0%
how holders react when this stock falls
On quiet Qs
+0.3%
−10% to +10% baseline
On rallies (+10%+)
-5.6%
how they react when this stock rises
Holders' portfolio flow this Q
+3.7%
inflows — adds are organic
Sellers' portfolio flow this Q
+4.7%
Sellers grew AUM elsewhere — opinionated cut of this stock.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-2.3%
Holder mid (any stock)
-4.9%
Holder rally (any stock)
-13.0%
Biggest decreases this quarter
Redmile Group, LLC−$1.1Mα-5.7Woodline Partners LP−$453Kα-0.1JPMORGAN CHASE & CO−$442Kα-0.2Seven Fleet Capital Management LPexited−$337KRICE HALL JAMES & ASSOCIATES, LLCexited−$180KDIADEMA PARTNERS LPexited−$177KMARSHALL WACE, LLP−$106Kα+0.6CANADA PENSION PLAN INVESTMENT BOARDexited−$75KPersistent Asset Partners Ltdexited−$47KEngineers Gate Manager LPexited−$37K
New buyers this quarter
Top-5 holders · 35.0%
TANG CAPITAL MANAGEMENT LLC--
CITADEL ADVISORS LLC--
Blue Owl Capital Holdings LP--
ADAR1 Capital Management, LLC--
ACADIAN ASSET MANAGEMENT LLC--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
TRV GP III, LLC—FMR LLC524Deep Track Capital, LP—Redmile Group, LLC772KCHI Advisors LLC—EVENTIDE ASSET MANAGEMENT, LLC—Avidity Partners Management LP—PRICE T ROWE ASSOCIATES INC /MD/—First Light Asset Management, LLC—Laurion Capital Management LP413K
Analyst Coverage
Analyst Coverage
Price Targets
Last Quarter (1 analysts)$3.0013810.0%
Last Year (1 analysts)$3.0013810.0%
Current Price$1.26
Analyst Ratings
8
7
Buy: 8Hold: 7Sell: 1Consensus: Buy
Corporate
Insider Trading (last 12mo)
Open-market only (Form 4 P-Purchase + S-Sale). Excludes grants, option exercises, tax withholding, gifts.
Officers & directors
Buys ($, 12mo)
$0
0 txns · 0 insiders · 0 sh
Sells ($, 12mo)
$164K
4 txns · 4 insiders · 127,828 sh
Recent transactions
| Date | Side | Insider | Title | Shares | Price | Dollars | Owned $ |
|---|---|---|---|---|---|---|---|
| 2026-01-20 | SELL | Cheung Lily | officer: Chief Human Resource Officer | 7,534 | $1.28 | $10K | $57K |
| 2026-01-20 | SELL | Coulie Bernard | director, officer: President and CEO | 89,375 | $1.28 | $114K | $647K |
| 2026-01-20 | SELL | Cummings Keith Lamont | officer: Chief Financial Officer | 24,002 | $1.28 | $31K | $380K |
| 2026-01-20 | SELL | Kuo Minnie | officer: Chief Operating Officer | 6,917 | $1.28 | $9K | $48K |
Order Flow (FINRA, ~3w lag)
35.1%retail-8.1pp
19.5%dark+4.7pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
PLIANT THERAPEUTICS, INC.: Defensive Moats and Massive Layoffs in a Race Against Liquid Exhaustion
Overall Risk
7/10
Fraud
2/10
Dilution
8/10
Insolvency
7/10
Earnings Overstated
2/10
Hidden Liabilities
4/10
Legal
4/10
Audit Warnings
3/10
Hidden Upside
4/10
Contextually Acceptable
6/10